Redefining Breast Cancer Detection

Transforming breast cancer detection for all women.

Breast cancer is the most common cancer in women of all ages globally, with the highest mortality rate. 12.9%of women will experience breast cancer in their lifetime (that’s 500 million women alive today). Survival rates are over 99% if treatment starts while it’s still localised in the breast. Survival rates drop significantly once it’s been able to spread.

Early detection is critical in reducing the number of women who will die from breast cancer.

Mi~Scan® is a unique device that measures breast tissue properties, before a mammogram. This enables clinicians to choose the best imaging technique for each patient’s breast tissue composition

  • Unlike a mammogram, which uses X-rays, Micrima technology uses radio waves to scan. These are the same frequencies used by wi-fi or a mobile phone, making our device safe to use as frequently as required.

  • The handheld callipers are placed on either side of the breast, with only light contact necessary.

  • Micrima technology uses non-ionising radio waves which are safe for women of all ages and breast densities, as frequently as required.

Why do we want to transform breast cancer detection?

  • Early Detection

    Patients who have their breast cancers found early have significantly higher survival rates. Micrima are aiming to open breast cancer screening to all ages, to improve early detection.

  • Breast Density

    High breast density increases breast cancer risk and makes it difficult to detect cancer on a mammogram. Mi~Scan® provides a BI-RADS breast density score in one minute, for use in imaging selection and risk profiling.

  • Your User Experience

    Mammograms compress the breast, which can be uncomfortable for some women. Micrima technology requires no breast compression.

“What you’re developing is a new concept, and to be honest with you, that’s what we need because we can’t deliver using the current concept.”

- Dr Nisha Sharma, Clinical lead of Leeds NHS Foundation Trust Breast Services and Chair of the Micrima Clinical Advisory Board